Nasdaq

FDA Grants SeaStar Medical Two New Breakthrough Device Designations for SCD Therapy to Treat Systemic Inflammatory Response in Adult and Pediatric Patients Undergoing Cardiac ...

DENVER, April 08, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients ...
Seeking Alpha

SeaStar Medical (Nasdaq: ICU) Announces Positive Interim Safety Findings from Ongoing Study Evaluating the Selective Cytopheretic Device (SCD) in Children

Interim study data show that SCD treatment is safe to use in pediatric patients with Acute Kidney Injury (AKI) requiring continuous kidney replacement therapy (CKRT) The SCD is currently being ...
Nasdaq

Cardinal Health launches Kendall SCD SmartFlow™ Compression System

Next generation of the Kendall™ SCD Series delivers an all-in-one solution for deep vein thrombosis and pulmonary embolism prevention "We're proud to introduce the reimagined Kendall SCD device to our ...
WATE 6 On Your Side

FDA Grants SeaStar Medical’s Selective Cytopheretic Device Breakthrough Device Designation for Hepatorenal Syndrome

DENVER, Oct. 18, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation ...